氟伐他汀抗氧化改善心肌梗死大鼠心室重塑

被引：2

作者：

赵志宏

单江

项美香

徐耕

傅国胜

鲍晓峰

机构：

[1] 浙江大学医学院附属第二医院,浙江大学医学院附属第二医院,浙江大学医学院附属第二医院,浙江大学医学院附属第二医院,浙江大学医学院附属第二医院,浙江大学医学院附属第二医院浙江杭州,浙江杭州,浙江杭州,浙江杭州,浙江杭州,浙江杭州

来源：

浙江大学学报(医学版) | 2005年 / 05期

关键词：

氟伐他汀/药理学; 投药,口服; 心肌梗塞/血液; 心室; 疾病模型,动物;

D O I：

暂无

中图分类号：

R96 [药理学];

学科分类号：

100602 ; 100706 ;

摘要：

目的:探讨氟伐他汀长期应用对SD大鼠心肌梗死(AMI)心室重塑过程的影响及其机制。方法:结扎雄性大鼠左冠状动脉前降支,复制心肌梗死模型,将大鼠分为2组,AMI组(n=7)以蒸馏水灌胃,氟伐他汀组(n=8)以氟伐他汀20mg.k-g1.-d1灌胃;另设假手术2组,分别以蒸馏水和氟伐他汀灌胃。8周后心脏超声、血液动力学、心脏形态学分析;检测血浆总胆固醇(Tch)、一氧化氮(NO)、脂质过氧化物(LPO)、谷胱甘肽过氧化物酶(GPx)和心肌LPO水平;激光共聚焦显微镜检测超氧阴离子和NO的分布;RT-PCR、免疫组化检测诱导型一氧化氮合酶(NOS2)、p22phox的mRNA和蛋白水平表达。结果:与AMI组比较,氟伐他汀组左室舒张末压降低[(18.24±6.58vs10.74±4.71)mmHg,P<0.05]、右室相对重量减轻[(0.92±0.19vs0.71±0.13)g/kg,P<0.05]、左室后壁厚度减少[(3.04±0.28vs2.60±0.36)mm,P<0.05];AMI后射血分数无影响,但肺相对重量减轻[(5.79±2.92vs3.69±0.68)g/kg,P<0.05];血浆和心肌LPO水平降低[(8.64±0.59vs7.71±0.66)μmol/L,P<0.05;(3.12±0.38vs1.93±0.40)ng/μg.pro,P<0.01],NO的过度表达抑制和GPx水平增加[(436.87±47.22vs313.78±34.35)mg/dl,P<0.01;(66.13±8.31vs79.78±2.38)mg/dl,P<0.05]。氟伐他汀干预后增加NOS2、p22phoxmRNA和蛋白水平的表达均下降(P<0.01)。血浆总胆固醇水平减低,但无显著性差异[(59.40±14.15vs48.30±8.83)mg/dl,P>0.05]。结论:氟伐他汀参与了改善大鼠心肌梗死后心室重塑过程,其中可能包括抗氧化机制。

引用

页码：447 / 453+464 +464

页数：8

共 13 条

[1]

Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. HAYASHIDANI S,TSUTSUI H,SHIOMI T,et al. Circulation . 2002

[2]

Peroxynitrite inducednitration and inactivation of myofibrillar creatine kinase in experimental heart failure. MIHM M J,COYLE C M,SCHANBACHER B L,et al. Cardiovascular Research . 2001

[3]

Increased myocardial NADPH oxidase activity in human heart failure. HEYMES C,BENDALL J K,RATAJCZAK P,et al. Journal of the American College of Cardiology . 2003

[4]

3-Hydroxy-3-methylglutarylcoenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. HASEGAWA H,YAMAMOTO R,TAKANO H,et al. Journal of Molecular and Cellular Cardiology . 2003

[5]

Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. MILLER F J,J R. GUTTERMAN D D,RIOS C D,et al. Circulation Research . 1998

[6]

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. SERRUYS P W,DE FEYTER P,MACAYA C,et al. The Journal of The American Medical Association . 2002

[7]

Reduction of my ocardial infarct size by fluvastatin. TIEFENBACHER C P,KAPITZA J,DIETZ V,et al. American Journal of Physiology Heart and Circulatory Physiology . 2003

[8]

Progressive ventricular remodeling in rat with myocardial infarction. PFEFFER J M,PFEFFER M A,FLETCHER P J,et al. American Journal of Physiology . 1991

[9]

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. TAKEMOTO M,LIAO J K. Arteriosclerosis and Thrombosis . 2001

[10]

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. TAKEMOTO M,NODE K,NAKAGAMI H,et al. The Journal of Clinical Investigation . 2001

← 1 2 →